SUMMARY
interval (CI) 0·211-0·356, P = 0·001), as well as fibrinogen concentrations, platelet counts, international normalised ratio (INR) and activated Partial Thromboplastin Time (aPTT), had a significant linear correlation with the MA on the TEG. Ionised calcium concentrations and its interaction term with platelet count were both significantly associated with the MA on the TEG (slope of the regression line 1·1 per 0·1 mmol L −1 increment, 95%CI 0·3 to 1·9, P = 0·011), after adjusting for fibrinogen concentrations, platelet counts, INR and aPTT.
Conclusions
Ionised calcium concentrations had a concentration-dependent association with in vitro clot strength after adjusting for other coagulation abnormalities in patients with coexisting coagulopathy.
Maintaining a normal ionised calcium concentration, >1 mmol L −1
, during critical bleeding is recommended.
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haemorrhage Calcium has a fundamental role as a cofactor in enzymatic reactions, transmembrane ion flux, muscle contraction, neuronal activity, coagulation cascade, platelet aggregation, regulation of vasomotor tone and cardiac contractility (Kauvar et al., 2006; Lier et al., 2008; Sihler & Napolitano, 2010) .
Hypocalcaemia may occur in patients with substantial amount of bleeding requiring transfusion of blood products (Dzik & Kirkley, 1988 ; British Committee for Standards in Haematology et al., 2006) .
Citrate toxicity has been suggested as the mechanism of hypocalcaemia during massive transfusion (Hayes et al., 1980; Dzik & Kirkley, 1988) , however, recent evidence suggests that intravenous colloid solutions and ischaemia reperfusion can also induce hypocalcaemia and hypocalcaemiainduced coagulopathy (Vivien et al., 2005) .
Although an in vitro study demonstrated that ionised calcium concentrations >0·56 mmol L −1 would be adequate for clot formation in blood donated from healthy volunteers (James & Roche, 2004) , clinical studies indicate that even mild hypocalcaemia may contribute to a higher risk of bleeding requiring multiple transfusions and mortality in patients with critical bleeding (Lier et al., 2008; Ho & Leonard, 2011; Magnotti et al., 2011) . This discrepancy may due to the fact that the effect of mild hypocalcaemia on bleeding may only be apparent in the presence of coexisting coagulopathy.
The commonly used standard tests of haemostasis, such as International Normalised Ratio (INR), activated Partial Thromboplastin Time (aPTT), have had their limitations for many reasons, most being time based and failing to give relevant information about the nature and stability of the plateletfibrin clot which may be affected by ionised calcium concentrations.
We hypothesised that hypocalcaemia may have a concentration-dependent effect on in vitro clot strength in patients with coexisting coagulopathy and conducted a retrospective cohort study to assess whether hypocalcaemia is associated with reduced in vitro clot strength after adjusting for coexisting coagulopathy. (Gibbs, 2011) . According to the recommendation of the manufacturer of the TEG machine, a MA < 54 mm or an angle <47° was considered as having a reduced in vitro clot strength. Two channels of TEG, one using kaolin alone as activating agent and the other using kaolin with heparinase, were conducted for all study patients. All whole blood samples were tested within 4 min of sampling at the patient's body temperature. Because some study patients might have received unfractionated heparin subcutaneously for venous thromboembolism prophylaxis, TEG data on the MA of the TEG tracing from the heparinase channel were used in this study for consistency purpose.
MATERIALS AND METHODS

After obtaining
Statistical analysis
If we assumed coagulation and calcium concentration results were available in 500 patients and 100
), and a reduced in vitro clot strength was also observed in 100 patients, this sample size would have >80% power to detect a relative risk difference of >2·0 in risk of a reduced in vitro clot strength between patients with and without hypocalcaemia, if the incidence of hypocalcaemia among those without reduced in vitro clot strength was 25%.
The quantitative relationship between ionised calcium concentrations and MA on the TEG was first analysed by a scatter plot, using Pearson correlation coefficient (r) to assess the degree of linear relationship between these two variables. The relationship between ionised calcium concentrations and MA was then further analysed after adjusting for platelet counts, INR, aPTT and fibrinogen concentrations in a multiple linear regression. During the modelling process, no variables were removed in the multiple linear regression analysis. Because age itself was unlikely to be related to the in vitro clot strength, this factor was not analysed in the multivariate linear regression. Transfusion requirements and blood pH were not recorded in this dataset, and hence, they were also not analysed in the multivariate analysis.
As a sensitivity analysis, trauma diagnosis and four interaction terms between ionised calcium concentrations and platelet count, INR, aPTT or fibrinogen concentration were also entered to the full multivariate model to assess whether they would increase the model's predictive ability in terms of adjusted coefficient of determination (R 2 ). Insignificant interaction terms (P > 0·05) were then removed by a backward stepwise procedure to improve the precision of the final results of this sensitivity analysis. A P-value <0·05 was taken as significant in this study, and all analyses were twotailed and conducted by spss for Windows (version 22.0, 2014, IBM, Chicago, IL, USA).
RESULTS
Of the 780 patients who were tested with a TEG during the study period, 610 patients had a concomitant ionised calcium concentration measured. The mean ionised calcium of the patients was 1·10 mmol L −1 (interquartile range: 1·04-1·17) (Fig. 1) , and 235 (38 · 5%) of them had
). The distribution of the MA among those with hypocalcaemia is described in Fig. 2 . The patients with hypocalcaemia were more likely to have cardiac surgery and were associated with thrombocytopenia, hypofibrinogenaemia, a prolonged INR or aPTT, and a smaller MA on the TEG compared with patients without hypocalcaemia ( ) (100 vs 22%, P = 0·001) were both associated with an increased risk of having reduced in vitro clot strength.
As a continuous predictor, ionised calcium concentrations had a significant correlation with MA on the TEG [r = 0·285, 95% confidence interval (CI) 0·211-0·356, P = 0·001] (Fig. 3) , with ionised calcium <1·0 mmol L −1 appeared to be the likely cut-point for MA to be affected by ionised calcium (Fig. 4) . Among all the predictors assessed, fibrinogen concentrations and platelet counts were more important than ionised calcium concentrations, INR and aPTT in explaining the variability of the final multivariate model.
In the sensitivity analysis, the only significant interaction term was between ionised calcium concentration and platelet count (with a negative regression coefficient), suggesting that changing ionised calcium concentrations would be associated with a larger change in in vitro clot strength in the presence of thrombocytopenia. The adjusted R 2 of the model was further improved by incorporating the interaction term between ionised calcium concentrations and platelet count (0·345 vs 0·326).
Trauma diagnosis was, however, not significantly associated with an increased risk of reduced in vitro clot strength (P = 0·448), after adjusting for ionised calcium concentration and other coagulation parameters.
DISCUSSION
This study showed that hypocalcaemia was common in patients with abnormal coagulation parameters, and ionised calcium concentrations had a concentration-dependent association with in vitro clot strength measured by a TEG in patients who were at risk of bleeding or had active bleeding, particularly when there was coexisting thrombocytopenia. These results are clinically relevant and require careful consideration.
First, our results confirmed that hypocalcaemia was common in patients who had critical bleeding and coexisting coagulopathy (Lier et al.,2008; Ho & Leonard, 2011) . Hypocalcaemia can be induced by transfusion of blood products such as fresh frozen plasma as well as intravenous fluid (Vivien et al., 2005; Ho & Leonard, 2011; Magnotti et al., 2011) , and these therapies can also induce haemodilution and coagulopathy at the same time in patients with critical bleeding. As such, it is possible that any adverse associations between hypocalcaemia and increased transfusion requirements or mortality of patients who have critical bleeding may be purely related to confounding. A previous healthy volunteer study inducing hypocalcaemia in normal blood samples in vitro showed that hypocalcaemia did not appear to have any apparent effect on the MA of the TEG tracing provided the ionised calcium concentrations were above 0·56 mmol L −1 (James & Roche, 2004) . This study was, however, limited by the use of blood samples without coexisting coagulopathy and, hence, whether mild hypocalcaemia may contribute to an increased risk of bleeding in patients with coexisting hypocalcaemia and abnormal coagulation parameters remains uncertain. Our results have extended the implication of this mechanistic study and showed that even mild hypocalcaemia may have some effect on the strength of the clot formation, as measured by the TEG, in patients with coexisting coagulopathy. Recent observational studies suggested that hypocalcaemia may be associated with a higher risk of intracerebral haemorrhage after thrombolytic therapy (Guo et al., 2015) and a larger haematoma volume in haemorrhagic stroke compared with those without hypocalcaemia (Inoue et al.,2013) . Given previous studies also showed that calcium is an essential cofactor for vitamin Kdependent coagulation factors (factors II, VII, IX, X) and platelet aggregation, and citrate is a very effective regional anticoagulant (Brass et al., 2005; Schilder et al., 2014) , our results certainly support the current critical bleeding and transfusion guidelines in recommending that ionised calcium concentrations should be maintained at a normal range in patients with critical bleeding (British Committee for Standards in Haematology et al., 2006; Spahn et al.,2013) .
Second, our results confirmed the increasing recognition of the importance of platelets and fibrinogen in the pathogenesis of critical bleeding, haemostasis and thrombosis Hagemo et al., 2014) . Our multivariate analysis results showed that fibrinogen concentrations and platelet counts certainly had a larger effect on in vitro clot strength than hypocalcaemia. As such, normalising hypofibrinogenaemia and thrombocytopenia should take a higher priority than correcting hypocalcaemia in the management of critical bleeding. These results were different from our previous work which showed that hypocalcaemia was more important than hypofibrinogenaemia or thrombocytopenia in critial bleeding (Ho & Leonard, 2011) . This difference could, at least in part, be explained by the use of fresh frozen plasma in patients with more severe bleeding and as fresh frozen plasma can also cause hypocalcaemia, this could confound the strength of association between mortality and hypocalcaemia. Nevertheless, the sensitivity analysis of this study suggested that correcting hypocalcaemia may have a larger effect on improving in vitro clot strength in the presence of thrombocytopenia. It is thus prudent to correct both hypocalcaemia and thrombocytopenia simultaneously for patients who are actively bleeding. Third, there are also other point-of-care whole blood coagulation tests, including ROTEM or the new TEG6s, which can be used to assist management of critical bleeding. Because most institutions use citrated blood samples for a ROTEM test (or the new TEG6s), any potential adverse effect of hypocalcaemia on in vitro clot strength, as demonstrated in this study, would not be apparent if the analysis is conducted on citrated blood samples. Ionised calcium concentrations should be measured and hypocalcaemia should be excluded when citrated blood samples are used for point-of-care whole blood clotting testing to guide transfusion management in critical bleeding. Colinearity was not significant between the variables (r < 0·5) and the R 2 of the model was 0·333. The regression standard error of the regression model was 10·2, suggesting that we can expect the model to be accurate in predicting the MA within approximately ±20·4 mm at a 95% confidence level. The maximum Cook's distance was 0·08 confirming that there were no outliers or excessive leverage in the data points used to generate this model. Residual plot suggested that the zero mean, constant variance and independence assumptions for ionised calcium concentrations were met and the QQ plot suggested that normality assumption for the regression analysis was met. The adjusted R 2 of a reduced model by removing one predictor was substantially lower after removing fibrinogen (R 2 = 0·254) or platelet count (adjusted R 2 = 0·272), than ionised calcium (R 2 = 0·318), INR (R 2 = 0·327) and aPTT (R 2 = 0·341).
